ArticleBMC complementary medicine and therapies2025
Modified Pulsatilla decoction alleviates DSS-induced colitis in mice by modulating gut microbiota and promoting IL-10 and IL-22 expression.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPulsatilla decoction (PD), a traditional Chinese formulation composed of Pulsatillae Radix (Pulsatilla chinensis), Coptidis Rhizoma (Coptis chinensis), Phellodendri Cortex (Phellodendron chinense), and Fraxini Cortex (Fraxinus chinensis), has long been used to treat chronic colitis. Previous studies demonstrated its antidiarrheal effects and proposed underlying mechanisms. Building on these findings, this study aimed to optimize PD by refining its bioactive components to develop a more effective formulation.
methodsAn in vitro assay was conducted using two strains of lactic acid bacteria to assess the impact of PD components on their growth. The growth and lactic acid production of these bacteria were assessed in response to the polysaccharides and small molecules present in PD. A modified PD (mPD) was created by removing components with adverse effects on the beneficial bacteria. The efficacy of mPD was evaluated in a dextran sulfate sodium (DSS)-induced colitis mouse model, with assessments including the disease activity index, intestinal inflammation, cytokine levels, macrophage infiltration, microbiota composition, and short-chain fatty acid (SCFA) levels.
resultsMethanol extracts from Coptidis Rhizoma (CR) and Phellodendri Cortex (PC) were found to inhibit lactic acid bacteria growth significantly versus other extracts. The mPD showed significantly improved efficacy compared to the original PD. It demonstrated superior anti-inflammatory effects, promoted tissue repair, increased levels of anti-inflammatory cytokines such as IL-10 and IL-22, and enhanced SCFA production. Furthermore, mPD favorably altered gut microbiota by reducing the Akkermansiaceae-to-Lachnospiraceae ratio, thereby effectively alleviating colitis symptoms.
conclusionAfter removing components that suppressed Lactobacillus proliferation, mPD exhibited greater efficacy against DSS-induced colitis. This improvement is likely associated with strengthened modulation of gut microbiota and inflammatory pathways. These results support microbiota-guided herbal optimization as a rational strategy for colitis management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.